# Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

**Authors:** Mototsugu Oya, Shuichi Kaneko, Tsuneo Imai, Toshiaki Tsujino, Toshiyuki Sunaya, Yutaka Okayama

PMC · DOI: 10.1007/s00280-023-04587-8 · 2023-09-16

## Full-text entities

- **Diseases:** renal cell, hepatocellular and thyroid carcinoma (MESH:D002292), renal impairment (MESH:D007674)

---
Source: https://tomesphere.com/paper/PMC11043094